SG159525A1 - Vaccine - Google Patents

Vaccine

Info

Publication number
SG159525A1
SG159525A1 SG201000794-6A SG2010007946A SG159525A1 SG 159525 A1 SG159525 A1 SG 159525A1 SG 2010007946 A SG2010007946 A SG 2010007946A SG 159525 A1 SG159525 A1 SG 159525A1
Authority
SG
Singapore
Prior art keywords
hpv
vaccine
protein
delivery
immunogenic fragment
Prior art date
Application number
SG201000794-6A
Other languages
English (en)
Inventor
Brigitte Desiree Alberte Colau
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36992675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG159525(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0509010A external-priority patent/GB0509010D0/en
Priority claimed from PCT/EP2005/006461 external-priority patent/WO2005123125A1/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of SG159525A1 publication Critical patent/SG159525A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
SG201000794-6A 2005-04-26 2006-04-24 Vaccine SG159525A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67482905P 2005-04-26 2005-04-26
GB0509010A GB0509010D0 (en) 2005-05-03 2005-05-03 Vaccine
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52

Publications (1)

Publication Number Publication Date
SG159525A1 true SG159525A1 (en) 2010-03-30

Family

ID=36992675

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201000794-6A SG159525A1 (en) 2005-04-26 2006-04-24 Vaccine

Country Status (12)

Country Link
US (1) US20090181052A1 (no)
EP (1) EP1877086A2 (no)
JP (1) JP2008539184A (no)
KR (1) KR20080005585A (no)
AR (1) AR054259A1 (no)
AU (1) AU2006239422A1 (no)
CA (1) CA2606092A1 (no)
EA (1) EA013326B1 (no)
MX (1) MX2007013472A (no)
NO (1) NO20075194L (no)
SG (1) SG159525A1 (no)
WO (1) WO2006114312A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP6022159B2 (ja) * 2008-07-31 2016-11-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗ｈｐｖワクチン
EP2444103B1 (en) * 2009-06-19 2017-12-20 Eyegene Inc. Vaccine for cervical cancer
ES2762230T3 (es) 2011-06-24 2020-05-22 Merck Sharp & Dohme Formulaciones de vacuna contra el HPV que comprenden un adyuvante de aluminio y métodos de producción de las mismas
MX2022009964A (es) 2020-02-14 2022-09-19 Merck Sharp & Dohme Llc Vacuna contra hpv.
WO2023014853A1 (en) 2021-08-06 2023-02-09 Merck Sharp & Dohme Llc Hpv vaccine
CA3229064A1 (en) 2021-08-19 2023-02-23 Andrew Bett Thermostable lipid nanoparticle and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0105606D0 (en) * 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
WO2004056389A1 (en) * 2002-12-20 2004-07-08 Glaxosmithkline Biologicals Sa Hpv-16 and -18 l1 vlp vaccine
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast

Also Published As

Publication number Publication date
WO2006114312A3 (en) 2007-04-05
WO2006114312A2 (en) 2006-11-02
EA013326B1 (ru) 2010-04-30
MX2007013472A (es) 2008-04-02
KR20080005585A (ko) 2008-01-14
US20090181052A1 (en) 2009-07-16
CA2606092A1 (en) 2006-11-02
EA200702079A1 (ru) 2008-04-28
JP2008539184A (ja) 2008-11-13
AR054259A1 (es) 2007-06-13
NO20075194L (no) 2008-01-18
AU2006239422A1 (en) 2006-11-02
EP1877086A2 (en) 2008-01-16

Similar Documents

Publication Publication Date Title
SG159525A1 (en) Vaccine
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
EP4219566A3 (en) Recombinant rsv antigens
UA85536C2 (en) Viral antigens
WO2007030810A3 (en) Multiparameter whole blood monitor and method
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
NZ529881A (en) Capsular polysaccharide solubilisation and combination vaccines
WO2006065553A3 (en) Glycoconjugate vaccines containing peptidoglycan
HK1062029A1 (en) Multiplication of viruses in a cell culture
WO2007014094A3 (en) Method of and system for predicting dose delivery
WO2007117303A3 (en) Combination vaccine comprising an attenuated bovine viral diarrhea virus
MY169275A (en) Method of immunization against the four serotypes of dengue
WO2007081896A3 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
WO2003063899A3 (en) Vaccine adjuvant based on a cd4 0 ligand
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
WO2009085025A3 (en) System and method for sparql-query processing using parametrized-sparql-query in dbms-based systems
PL1949913T3 (pl) Immunostymulująca kombinacja do profilaktyki i leczenia wirusowego zapalenia wątroby typu c
WO2006007555A3 (en) Rotavirus antigens
WO2003059385A3 (en) Hiv vaccine and method of use
MXPA02012249A (es) Peptidos, composiciones y metodos para el tratamiento de burkholderia cepacia.
WO2004043404A3 (en) Process for designing inhibitors of influenza virus non-structural protein 1
TW200612983A (en) Vaccine
WO2003060088A3 (en) Viral vaccine production method
WO2002009749A3 (en) Respiratory syncytial virus vaccine